Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.67 ▲ +0.05
(+3.09%)
MKT CAP: $233.0M • VOL: 852.4K
52W L $1 52W H $3
ROARABLE / RQD
D- • 39/100
PIOTROSKI
2 / 9
IKT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $260.5K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$52.0M | -$28.6M | -$20.1M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$48.3M | -$27.5M | -$19.0M |
| EBITDA (Normalized) | -$52.0M | -$28.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.8M | -$19.1M | -$18.1M |
| Capital Expenditures (CapEx) | $13.4K | $0 | — |
| Free Cash Flow (FCF) | -$27.8M | -$19.1M | -$18.1M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $178.8M | $97.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $172.9M | $94.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IKT.